VANCOUVER, British Columbia, March 19, 2012 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) (“QLT” or the “Company”) today announced that its commercial product, Visudyne® (verteporfin for injection), was granted orphan drug designation for the potential treatment of chronic or recurrent central serous chorioretinopathy (CSC) from the U.S. Food and Drug Administration (FDA).
